By Barbara Obstoj-Cardwell. Editor
With the fourth-quarter financial results season starting, Johnson & Johnson, as ever, was the first big pharma to release figures on Tuesday, and these beat expectations. US biotech Incyte last Tuesday announced a clinical setback for its parsaclisib trial and decision to opt out of continued development of MCLA-145 with Mersus. Troubled US biotech Biogen has entered a deal to sell its nearly 50% stake in Samsung Bioepis, the biosimilars joint venture Samsung BioLogics, for $2.3 billion. TG Therapeutics suffered a setback with the US Food and Drug Administration putting a partial clinical hold on its study of leukemia candidate Ukoniq, but the news was more to do with how it slipped out.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze